In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Tango Therapeutics Inc (NASDAQ: TNGX) closed at $2.35 in the last session, down -0.42% from day before closing price of $2.36. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
We take a closer look at TNGX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.00 and its Current Ratio is at 8.00. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on July 17, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On February 12, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $18.Piper Sandler initiated its Overweight rating on February 12, 2024, with a $18 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 04 ’25 when Barry Douglas sold 2,774 shares for $2.99 per share. The transaction valued at 8,289 led to the insider holds 68,570 shares of the business.
Barry Douglas sold 2,556 shares of TNGX for $8,081 on Feb 05 ’25. The General Counsel now owns 66,014 shares after completing the transaction at $3.16 per share. On Feb 04 ’25, another insider, Beckman Daniella, who serves as the Chief Financial Officer of the company, sold 4,284 shares for $2.99 each. As a result, the insider received 12,801 and left with 154,232 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 5.82 while its Price-to-Book (P/B) ratio in mrq is 1.10.
Stock Price History:
Over the past 52 weeks, TNGX has reached a high of $12.02, while it has fallen to a 52-week low of $2.35. The 50-Day Moving Average of the stock is -19.73%, while the 200-Day Moving Average is calculated to be -63.83%.
Shares Statistics:
A total of 107.41M shares are outstanding, with a floating share count of 48.36M. Insiders hold about 54.98% of the company’s shares, while institutions hold 56.47% stake in the company.
Earnings Estimates
The performance of Tango Therapeutics Inc (TNGX) in the stock market is under the watchful eye of 9.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.32 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.11 and -$1.26 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$1.44, with 9.0 analysts recommending between -$1.28 and -$1.54.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $8.02M. It ranges from a high estimate of $15.6M to a low estimate of $5M. As of the current estimate, Tango Therapeutics Inc’s year-ago sales were $5.43MFor the next quarter, 9 analysts are estimating revenue of $7.21M. There is a high estimate of $8.3M for the next quarter, whereas the lowest estimate is $6.25M.
A total of 9 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $53.6M, while the lowest revenue estimate was $42.95M, resulting in an average revenue estimate of $45.99M. In the same quarter a year ago, actual revenue was $36.53MBased on 9 analysts’ estimates, the company’s revenue will be $29.34M in the next fiscal year. The high estimate is $43.45M and the low estimate is $25M.
